🔬 DLBCL Prognosis Calculator
Estimate the prognosis for Diffuse Large B-Cell Lymphoma using the Revised International Prognostic Index (R-IPI). Answer 5 clinical questions to determine survival estimates.
📊 DLBCL Prognosis Results
What Is DLBCL?
DLBCL stands for Diffuse Large B-Cell Lymphoma. It is a very aggressive neoplasm that can easily spread to different parts of the body and cause symptoms connected to rapidly growing cancer cell masses.
💡 Lymphoma is a type of blood cancer that develops from white blood cells called lymphocytes. Lymphomas differ from leukemia (another type of blood cancer) because they may form visible, solid tumors; their typical places of growth are lymph nodes, spleen, and thymus.
DLBCL is usually detected among older people — it's a relatively common lymphoma. The most advanced type, DLBCL stage 4, carries approximately a 65% chance of survival.
Signs and Symptoms of DLBCL
Lymphomas may go unnoticed for a longer period of time, up to the point when they cause severe and sudden complications. Patients usually experience so-called B-symptoms, which can be easily overlooked:
- 😴 Fatigue
- 💧 Night sweats
- ⚖️ Weight loss without any apparent reason
- 🌡️ Unexplained fever
Sudden events that require immediate medical attention include:
- Superior vena cava syndrome — swelling and reddening of the upper body caused by blockage of a main vessel carrying blood back to the heart
- Severe shortness of breath — caused by blockage of airways by enlarged lymph nodes
Diffuse Large B-Cell Lymphoma Staging
Staging follows the Ann-Arbor scale:
| Stage | Description |
|---|---|
| I | One lymph node region or its surroundings |
| II | Two or more sites on the same side of the diaphragm |
| III | Sites on both sides of the diaphragm |
| IV | Disease spread to liver, kidneys, lungs, or central nervous system |
Modifiers:
- B — presence of B symptoms (night sweats, fever, weight loss)
- A — absence of B symptoms
- S — disease has spread to the spleen
- E — extranodal disease (outside of lymph nodes)
- X — biggest affected site is larger than 10 cm, or mediastinum takes more than 1/3 of chest on X-ray
How to Calculate DLBCL Prognosis with the IPI Score
Our calculator uses the Revised IPI (R-IPI) score — a more accurate prognosis method updated after introducing rituximab to DLBCL treatment. Answer the 5 questions in the table below and sum all points:
| Factor | Yes | No |
|---|---|---|
| Age > 60 years? | 1 | 0 |
| Stage III or IV? | 1 | 0 |
| Elevated serum LDH? | 1 | 0 |
| ECOG/Zubrod ≥ 2? | 1 | 0 |
| > 1 extranodal site? | 1 | 0 |
R-IPI Risk Groups
| Score | Risk Group | 4-yr PFS | 4-yr OS |
|---|---|---|---|
| 0 | Very Good Prognosis | 94% | 94% |
| 1–2 | Good Prognosis | 80% | 79% |
| 3–5 | Poor Prognosis | 53% | 55% |
💡 Age adjusted IPI calculators compare prognosis within the same age group and use only 3 factors (Stage, LDH, ECOG) instead of 5.
Frequently Asked Questions
What is the survival rate for DLBCL?
Survival rates depend heavily on the IPI score. With modern R-CHOP (rituximab-based) treatment, patients with a score of 0 have a 94% 4-year overall survival rate, while those scoring 3–5 have approximately 55%.
Is DLBCL curable?
Yes, DLBCL is potentially curable, especially when detected early. Standard first-line treatment is R-CHOP chemotherapy (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone).
What are ECOG performance status levels?
ECOG performance status measures how well a patient can perform daily activities:
- 0 — Fully active, no restrictions
- 1 — Restricted in strenuous activity but ambulatory
- 2 — Ambulatory and capable of self-care but unable to work
- 3 — Limited self-care, confined to bed/chair >50% of waking hours
- 4 — Completely disabled, totally confined to bed/chair